Zymeworks receives FDA fast track designation for ovarian cancer drug
Tweet Send to a Friend
Zymeworks Inc. (NASDAQ: ZYME) announced that the U.S. Food and Drug Administration has granted Fast Track designation to ZW191, an ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


